Ocugen
Founded Year
2013Stage
Loan | IPOTotal Raised
$19.73MMissing: Ocugen's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Ocugen's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Ocugen
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Ocugen is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Ocugen Patents
Ocugen has filed 9 patents.
The 3 most popular patent topics include:
- Amines
- Autoimmune diseases
- Beta blockers
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
9/14/2018 | 1/17/2023 | Orthopedic surgical procedures, Joints, Skeletal system, Biomaterials, Extracellular matrix proteins | Grant |
Application Date | 9/14/2018 |
|---|---|
Grant Date | 1/17/2023 |
Title | |
Related Topics | Orthopedic surgical procedures, Joints, Skeletal system, Biomaterials, Extracellular matrix proteins |
Status | Grant |
Latest Ocugen News
Mar 7, 2023
Seven Amarin directors resign after Sarissa proxy win Plus: Ocugen expands Quan Vu’s role to CBO and CFO, and updates from BPGbio and MediWound By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst March 7, 2023 1:45 AM UTC Seven independent board members at Amarin Corp. plc (NASDAQ:AMRN) resigned Monday following the victory of activist investor Sarissa Capital Management in a proxy contest against the company’s board last week. The resigning board members are Adam Berger, Erin Enright, Geraldine Murphy, Kristine Peterson, Murray Stewart, Jan van Heek and Alfonso “Chito” Zulueta. Last week, Amarin shareholders voted to elect all seven of Sarissa’s board nominees and remove Per Wold-Olsen as chairman. An estimated 80% of shareholders voted in support of Sarissa. Ocular gene and cell therapies and vaccines company Ocugen Inc. (NASDAQ:OCGN) expanded the role of CBO Quan Vu to include CFO. Vu joined Ocugen last month, before which he was COO and CBO at 180 Life Sciences Corp. (NASDAQ:ATNF)... BCIQ Company Profiles
Ocugen Frequently Asked Questions (FAQ)
When was Ocugen founded?
Ocugen was founded in 2013.
Where is Ocugen's headquarters?
Ocugen's headquarters is located at 5 Great Valley Parkway, Malvern.
What is Ocugen's latest funding round?
Ocugen's latest funding round is Loan.
How much did Ocugen raise?
Ocugen raised a total of $19.73M.
Who are the investors of Ocugen?
Investors of Ocugen include Paycheck Protection Program, Histogenics, Abdi Ibrahim, JSC Lancaster Group, Frank Leo and 4 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.